FDA approves first labeling revision for Zepbound since 2023 clearance
The first labeling update to Zepbound since its 2023 approval covers the patient Medication Guide, carton labels and prescribing insert, but the FDA record does not say what was changed.
Eli Lilly's Zepbound has revised carton labels, a revised Medication Guide and a revised package insert, according to the FDA record for the drug's application. The changes were approved March 28, 2024, as supplement S-003 to New Drug Application 217806, the first labeling update to the product since it was cleared for sale [1].
Zepbound is tirzepatide, a prescription medicine given by subcutaneous injection [1]. The original application was approved Nov. 8, 2023, on a priority review [1]. The FDA product table for NDA 217806 lists Zepbound in 0.5 mL strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg, and in KwikPen presentations from 10 mg/2.4 mL to 60 mg/2.4 mL [1]. Every entry in that table is listed as a prescription product with marketing status "Prescription" [1].
The March 2024 action is filed under three categories: container and carton labels, Medication Guide, and package insert [1]. Those categories cover different audiences. The Medication Guide is the patient-facing document that comes with the medicine, the package insert is the prescribing information, and carton and container labels appear on the packaging itself [1].
The FDA record does not describe what wording changed, what prompted the filing, or whether any new safety information was added. It also does not say whether the approved uses, the available strengths, or the way the drug is packaged and supplied were affected. The submission is classified as a labeling supplement, not an efficacy supplement such as a new indication [1].
The supplement appears as the earliest entry in the approval history for NDA 217806, less than five months after the original approval date [1]. The record does not state how long the review took, or when the revised materials reached pharmacies and patients.
Why it matters for patients
Labeling is the paper trail of a medicine: the sheet that comes with a prescription, the box the product is packed in, and the document a prescriber consults. A supplement covering these three categories means at least one of those items was rewritten [1].
Because the record lists only the categories, a patient who notices different wording on a Zepbound carton or Medication Guide cannot tell from this filing whether the change reflects new safety information, routine editing, or a packaging update. A safety-driven labeling change would typically come with a public communication from the FDA or the manufacturer; no such communication is described in this record [1].
The action does not change the drug's status in the FDA listing. All Zepbound entries remain prescription products under the same application, at the same listed strengths [1]. The record does not address price, insurance coverage or supply, and no details on those points have been disclosed for this supplement [1].
What happens next
The FDA page links to a label and an approval letter for the March 2024 supplement, but their contents are not summarized there [1]. Any later labeling actions for Zepbound would appear as new supplement entries on the same application record [1]. No next milestone tied to supplement S-003 has been reported.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.